• Something wrong with this record ?

External validation of a non-invasive vaginal tool to assess the risk of intra-amniotic inflammation in pregnant women with preterm labor and intact membranes

T. Cobo, XP. Burgos-Artizzu, S. Ferrero, J. Balcells, J. Bosch, A. Gené, C. Murillo, C. Rueda, D. Boada, MT. Sánchez-Antón, M. Kacerovsky, B. Jacobsson, M. Palacio

. 2025 ; 53 (2) : 170-178. [pub] 20241125

Language English Country Germany

Document type Journal Article, Validation Study

Persistent link   https://www.medvik.cz/link/bmc25009821

OBJECTIVES: To prospectively validate the diagnostic performance of a non-invasive point-of-care tool (Rapid IAI System), including vaginal alpha-fetoprotein and interleukin-6, to predict the occurrence of intra-amniotic inflammation in a Spanish cohort of patients admitted with a diagnosis of preterm labor and intact membranes. METHODS: From 2017 to 2022, we prospectively evaluated a cohort of pregnant women diagnosed with preterm labor and intact membranes admitted below 34+0 weeks who underwent amniocentesis to rule-in/out intra-amniotic infection and/or inflammation. Vaginal sampling was performed at the time of amniocentesis or within 24-48 h. Amniotic fluid IL-6, vaginal alpha-fetoprotein and vaginal IL-6 concentrations were measured using a point-of-care tool provided by Hologic Inc., "Rapid IAI System". We defined intra-amniotic inflammation when amniotic fluid IL-6 values were greater than 11.3 ng/mL. During recruitment, clinicians were blinded to the results of the point-of-care tool. The original prediction model proposed by Hologic Inc. to predict intra-amniotic inflammation was validated in this cohort of patients. RESULTS: We included 151 patients diagnosed with preterm labor and intact membranes. Among these, 29 (19.2 %) had intra-amniotic inflammation. The algorithm including vaginal IL-6 and alpha-fetoprotein showed an area under curve to predict intra-amniotic inflammation of 80.3 % (±5.3 %) with a sensitivity of 72.4 %, specificity of 84.6 %, positive predictive valuve (PPV) of 52.5 %, negative predictive value (NPV) of 92.9 %, and a positive likelihood ratio (LR+) of 4.6 and negative likelihood ratio (LR-) of 0.33. CONCLUSIONS: External validation of a non-invasive rapid point-of-care tool, including vaginal alpha-fetoprotein and IL-6, showed very good diagnostic performance for predicting the absence of intra-amniotic inflammation in women with preterm labor and intact membranes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009821
003      
CZ-PrNML
005      
20250429134717.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/jpm-2024-0178 $2 doi
035    __
$a (PubMed)39575693
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Cobo, Teresa $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain $u Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Departament de Cirurgia i Especialitats Medicoquirúrgiques, Universitat de Barcelona, Barcelona, Spain $u Center for Biomedical Research on Rare Diseases (CIBER-ER), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain $1 https://orcid.org/0000000331301829
245    10
$a External validation of a non-invasive vaginal tool to assess the risk of intra-amniotic inflammation in pregnant women with preterm labor and intact membranes / $c T. Cobo, XP. Burgos-Artizzu, S. Ferrero, J. Balcells, J. Bosch, A. Gené, C. Murillo, C. Rueda, D. Boada, MT. Sánchez-Antón, M. Kacerovsky, B. Jacobsson, M. Palacio
520    9_
$a OBJECTIVES: To prospectively validate the diagnostic performance of a non-invasive point-of-care tool (Rapid IAI System), including vaginal alpha-fetoprotein and interleukin-6, to predict the occurrence of intra-amniotic inflammation in a Spanish cohort of patients admitted with a diagnosis of preterm labor and intact membranes. METHODS: From 2017 to 2022, we prospectively evaluated a cohort of pregnant women diagnosed with preterm labor and intact membranes admitted below 34+0 weeks who underwent amniocentesis to rule-in/out intra-amniotic infection and/or inflammation. Vaginal sampling was performed at the time of amniocentesis or within 24-48 h. Amniotic fluid IL-6, vaginal alpha-fetoprotein and vaginal IL-6 concentrations were measured using a point-of-care tool provided by Hologic Inc., "Rapid IAI System". We defined intra-amniotic inflammation when amniotic fluid IL-6 values were greater than 11.3 ng/mL. During recruitment, clinicians were blinded to the results of the point-of-care tool. The original prediction model proposed by Hologic Inc. to predict intra-amniotic inflammation was validated in this cohort of patients. RESULTS: We included 151 patients diagnosed with preterm labor and intact membranes. Among these, 29 (19.2 %) had intra-amniotic inflammation. The algorithm including vaginal IL-6 and alpha-fetoprotein showed an area under curve to predict intra-amniotic inflammation of 80.3 % (±5.3 %) with a sensitivity of 72.4 %, specificity of 84.6 %, positive predictive valuve (PPV) of 52.5 %, negative predictive value (NPV) of 92.9 %, and a positive likelihood ratio (LR+) of 4.6 and negative likelihood ratio (LR-) of 0.33. CONCLUSIONS: External validation of a non-invasive rapid point-of-care tool, including vaginal alpha-fetoprotein and IL-6, showed very good diagnostic performance for predicting the absence of intra-amniotic inflammation in women with preterm labor and intact membranes.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a těhotenství $7 D011247
650    12
$a předčasná porodní činnost $x diagnóza $7 D007752
650    _2
$a dospělí $7 D000328
650    12
$a alfa-fetoproteiny $x analýza $x metabolismus $7 D000509
650    12
$a interleukin-6 $x analýza $x krev $x metabolismus $7 D015850
650    12
$a chorioamnionitida $x diagnóza $7 D002821
650    _2
$a prospektivní studie $7 D011446
650    12
$a plodová voda $x metabolismus $x chemie $7 D000653
650    _2
$a amniocentéza $x metody $7 D000649
650    _2
$a vagina $x metabolismus $7 D014621
650    _2
$a hodnocení rizik $x metody $7 D018570
650    _2
$a vyšetření u lůžka $7 D019095
650    _2
$a point of care testing $7 D000067716
650    _2
$a prediktivní hodnota testů $7 D011237
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Burgos-Artizzu, Xavier P $u MovumTech, Barcelona, Spain
700    1_
$a Ferrero, Silvia $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Balcells, Judith $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Bosch, Jordi $u Microbiology department, Center of Biomedical diagnostic, Hospital Clinic, ISGlobal, Barcelona, Spain
700    1_
$a Gené, Amadeu $u Microbiology department, Hospital Sant Joan de Déu, Barcelona, Spain
700    1_
$a Murillo, Clara $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Rueda, Claudia $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Boada, David $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Sánchez-Antón, Maria Teresa $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
700    1_
$a Kacerovsky, Marian $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Obstetrics and Gynecology, Hospital Most, Most, Czech Republic
700    1_
$a Jacobsson, Bo $u Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $u Department of Genetics and Bioinformatics, Area of Health Data and Digitalisation, Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Palacio, Montse $u BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetrícia I Neonatología, Fetal i+D Fetal Medicine Research Center, Barcelona, Spain $u Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain $u Center for Biomedical Research on Rare Diseases (CIBER-ER), Institute of Health Carlos III (ISCIII), Madrid, Spain
773    0_
$w MED00002887 $t Journal of perinatal medicine $x 1619-3997 $g Roč. 53, č. 2 (2025), s. 170-178
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39575693 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134712 $b ABA008
999    __
$a ok $b bmc $g 2311295 $s 1246902
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 53 $c 2 $d 170-178 $e 20241125 $i 1619-3997 $m Journal of perinatal medicine $n J Perinat Med $x MED00002887
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options